



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2025/011012

(22) International Filing Date:

10 January 2025 (10.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202410048317.6 11 January 2024 (11.01.2024) CN
202510015915.8 06 January 2025 (06.01.2025) CN

(71) Applicant: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US).

(72) Inventors: ZHU, Yi; 15318 NE 95th St, Redmond, Washington 98052 (US). WAN, Weili; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN). ZHUO, Shi; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN). LAI, Weirong; 139 Baili Road, Wenjiang District, Chengdu, Washington 611130 (US). ZHANG, Yong; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(74) Agent: WAN, Feng; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY-AURISTATIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF




Figure 8

(57) Abstract: The application provides, among others, antibody-drug conjugates formed from a bispecific antibody and an auristatin drug unit, or a pharmaceutically acceptable salt or solvate thereof, and methods of making and using thereof. The application further provides linker-drug compounds, their isomers, endo-, racemates, enantiomers, or mixtures thereof, or pharmaceutically acceptable salts or solvates thereof, and methods of making and using thereof.